| 0.0178 0.004 (25.35%) | 04-26 14:41 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.03 | 1-year : | 0.04 |
| Resists | First : | 0.02 | Second : | 0.03 |
| Pivot price | 0.01 |
|||
| Supports | First : | 0.01 | Second : | 0.01 |
| MAs | MA(5) : | 0.01 |
MA(20) : | 0.01 |
| MA(100) : | 0.03 |
MA(250) : | 0.24 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7 |
D(3) : | 8.7 |
| RSI | RSI(14): 39.5 |
|||
| 52-week | High : | 1.57 | Low : | 0.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EVFM ] has closed above bottom band by 17.7%. Bollinger Bands are 61.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.02 - 0.02 | 0.02 - 0.02 |
| Low: | 0.01 - 0.01 | 0.01 - 0.01 |
| Close: | 0.02 - 0.02 | 0.02 - 0.02 |
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Tue, 23 Apr 2024
Are Options Traders Betting on a Big Move in Evofem Biosciences (EVFM) Stock? - Yahoo New Zealand News
Thu, 18 Apr 2024
Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO – Company ... - Financial Times
Sun, 14 Apr 2024
Do Options Traders Know Something About Evofem Biosciences (EVFM) Stock We Don't? - Yahoo Movies Canada
Wed, 27 Mar 2024
EVFM Stock Earnings: Evofem Biosciences Reported Results for Q4 2023 - InvestorPlace
Wed, 20 Mar 2024
Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal - BioSpace
Thu, 01 Feb 2024
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
PNK
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 216 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 4.4 (%) |
| Shares Short | 8,680 (K) |
| Shares Short P.Month | 17,820 (K) |
| EPS | -1.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.76 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.05 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.02 |
| PEG Ratio | 0 |
| Price to Book value | -0.03 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2018-01-17 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|